Clin Lab. 2020 Apr 1;66(4). doi: 10.7754/Clin.Lab.2019.190712.
The aim of the study was to explore the expression level of miRNA-30 expression in patients with non-small cell lung cancer (NCLC) and analyze its correlation with clinicopathological features and prognosis.
Preoperative serum samples and paracancerous tumor-free tissues of 108 patients with NSCLC treated in our hospital as well as serum samples of 108 healthy subjects were collected from April 2015 to May 2018. The expression levels of miRNA-30 in tissue samples were detected by in situ hybridization and that of miRNA-30 mRNA in serum samples by real-time quantitative PCR (RT-qPCR). The difference in miRNA-30 expression in tumor-free tissues of NSCLC patients and NSCLC tissues of each stage was measured. The miRNA-30 mRNA levels in NSCLC patients was compared with those in healthy subjects. All subjects were divided into low-expression group (< mean) and high expression group (≥ mean) with the mean value of miRNA-30 levels being the critical value. The relationship between miRNA-30 levels and clinicopathological parameters (gender, age, lymph node metastasis, tumor size, TNM stage, degree of infiltration, and differentiation) was analyzed, and the prognosis of different serum miRNA-30 levels was compared based to follow-up data.
The expression level of miRNA-30 in cancer tissues and serum of NSCLD patients was significantly lower (p < 0.05, respectively). The results of ROC curve analysis showed that the area under the curve for the diagnosis of NSCLC using miRNA-30 was 0.802 (95% CI: 0.742 to 0.861, p < 0.001), with the diagnostic threshold being 0.798, sensitivity and specificity being 75.9% and 76.0%, respectively. Serum miRNA-30 levels in NSCLC patients were not associated with gender, age, and depth of infiltration (p > 0.05), but correlated with lymph node metastasis, tumor size, TNM stage, and degree of differentiation (p < 0.05). The median overall survival of the miRNA-30 low expression group was 23.0 months, which was shorter than the 36.0 months of high expression group, and the difference was statistically significant (p < 0.05).
miRNA-30 is lowly expressed in NSCLC patients and participates in the development of NSCLC. Moreover, NSCLC patients with low expression show poor prognosis. Thus, miRNA-30 features potential as a marker for NSCLC screening and prognosis prediction.
本研究旨在探讨非小细胞肺癌（NSCLC）患者中 miRNA-30 的表达水平，并分析其与临床病理特征和预后的关系。
收集我院收治的 108 例 NSCLC 患者术前血清样本及癌旁无肿瘤组织，以及 108 例健康对照者血清样本，采用原位杂交法检测组织样本中 miRNA-30 的表达水平，采用实时定量 PCR（RT-qPCR）法检测血清样本中 miRNA-30mRNA 的表达水平。比较 NSCLC 患者癌旁无肿瘤组织与各期 NSCLC 组织中 miRNA-30 的表达差异，比较 NSCLC 患者 miRNA-30mRNA 水平与健康对照者。所有患者均以 miRNA-30 水平的平均值为临界值分为低表达组（<平均值）和高表达组（≥平均值）。分析 miRNA-30 水平与临床病理参数（性别、年龄、淋巴结转移、肿瘤大小、TNM 分期、浸润程度、分化程度）的关系，并根据随访资料比较不同血清 miRNA-30 水平的预后。
NSCLD 患者癌组织和血清中 miRNA-30 的表达水平均显著降低（p<0.05）。ROC 曲线分析结果显示，miRNA-30 诊断 NSCLC 的曲线下面积为 0.802（95%CI：0.742 至 0.861，p<0.001），诊断阈值为 0.798，灵敏度和特异度分别为 75.9%和 76.0%。NSCLC 患者血清 miRNA-30 水平与性别、年龄、浸润深度无关（p>0.05），但与淋巴结转移、肿瘤大小、TNM 分期、分化程度有关（p<0.05）。miRNA-30 低表达组的中位总生存期为 23.0 个月，短于高表达组的 36.0 个月，差异有统计学意义（p<0.05）。
miRNA-30 在 NSCLC 患者中表达降低，参与 NSCLC 的发生发展。此外，miRNA-30 低表达的 NSCLC 患者预后不良。因此，miRNA-30 具有作为 NSCLC 筛查和预后预测标志物的潜力。
